Clinical trials: Dendritic Cell
Prostate Cancer
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
This study investigates the use of the patients own immune cells to treat prostate cancer. Cells are taken from the patient and grown in the laboratory to become specialized immune cells called dendritic cells.
- Trial name
- MUC1 (NCT00852007)
- Testing
- DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Anemia, Graft Versus Host Disease
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing…
- Conditions
- Anemia, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00003398
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Maryland, Baltimore
Advanced Hepatocellular Carcinoma
Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of PIK-PD-1 Cells in the treatment of advanced Hepatocellular Carcinoma. Methods: This study designs a novel therapy using PIK-PD-1 cells.
- Trial name
- NCT02632006
- Testing
- PIK-PD-1 cells, DC-PMAT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Military Medical University
Leukemia, Myelodysplastic Syndromes
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT00397579
- Testing
- DT388IL3
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03035331
- Testing
- Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Glioblastoma
Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma
The overall objective of this study is to preliminarily evaluate the efficacy and safety of Survivin-targeted DC Cell Injection in the postoperative treatment of newly diagnosed glioblastoma.
- Trial name
- NCT07715097
- Testing
- Survivin-targeted DC Cell Injection
- Volunteers
- 30 people
- Sponsor
- Beijing Tricision Biotherapeutics Inc
Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid…
- Conditions
- Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma
- Trial name
- NCT00012181
- Testing
- alvocidib, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Gestational Trophoblastic Tumor
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side…
- Conditions
- Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma
- Trial name
- NCT00004157
- Testing
- filgrastim, recombinant interleukin-11
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Kidney Cancer, Leukemia
Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation
RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00080873
- Testing
- Traumeel S
- Where
- 44 sites in United States, Australia and 2 more
- Volunteers
- 195 people
- Sponsor
- Children's Oncology Group
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients.
- Trial name
- TAGVEN (NCT07007052)
- Testing
- Venetoclax, Tagraxofusp
- Where
- 34 sites in France
- Volunteers
- 33 people
- Sponsor
- French Innovative Leukemia Organisation
Hormone-Refractory Prostate Cancer
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
This is a randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen-loaded dendritic cells (Provenge, APC8015) for asymptomatic, metastatic, hormone-refractory prostate cancer.
- Trial name
- NCT01133704
- Testing
- sipuleucel-T
- Volunteers
- 98 people
- Sponsor
- Dendreon
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004232
- Testing
- filgrastim, cyclosporine, methylprednisolone
- Where
- United States
- Sponsor
- Northwestern University
Lung Cancer
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103116
- Testing
- autologous dendritic cell cancer vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Edward Hirschowitz
Advanced Malignant Solid Tumors
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors.
- Trial name
- NCT05749627
- Testing
- Neoantigen peptide vaccine, Neoantigen-based DC immune preparation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes
1. Determine the feasibility of generation of autologous Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia in myeloid blast crisis (CML/BC) derived dendritic cell activated lymphocytes (DC/AL) in poor prognosis…
- Trial name
- NCT00038870
- Testing
- Dendritic Cell Activated Lymphocyte
- Sponsor
- M.D. Anderson Cancer Center
EBV Associated Lymphoid Neoplasms
KSD-101 in Patients With EBV-associated Hematological Malignancies
Epstein-Barr virus (EBV) is a double-stranded DNA virus belonging to the Gammaherpesvirinae subfamily of Herpesviridae. It primarily infects B cells and pharyngeal epithelial cells, and can also infect NK cells and T cells.
- Trial name
- NCT07525024
- Testing
- Autologous dendritic cell vaccine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Ruijin Hospital
Immune Disease
Effect of Anti-CD303 Antibodies in Autoimmune Diseases
The pathogenic role of type I interferons (IFNs) in the development of different autoimmune diseases has been extensively described in the literature.
- Trial name
- ANTI-CD303 (NCT03370627)
- Testing
- Monoclonal anti-cd303 antibody
- Where
- France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Lille
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with…
- Trial name
- NCT04277221
- Testing
- Autologous Dendritic Cell/Tumor Antigen, ADCTA
- Where
- 7 sites in Taiwan
- Volunteers
- 118 people
- Sponsor
- Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Non-small Cell Lung Cancer
Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer
Prospective study with the use of biological samples. The centers involved are the Thoracic Surgery and Surgery 1 Units of the San Gerardo Hospital in Monza.
- Trial name
- TUM-DC (NCT04789252)
- Testing
- Bioinformatics analysis of single cell transcriptomics data
- Where
- 2 sites in Italy
- Volunteers
- 64 people
- Sponsor
- University of Milano Bicocca